

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/072034 A1

(51) International Patent Classification⁷: **C07D 211/58**,
A61K 31/4468, C07D 409/12, 401/08, 405/04, 413/12,
413/14, A61P 25/18

(21) International Application Number:
PCT/EP2004/001211

(22) International Filing Date: 10 February 2004 (10.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03003526.5 17 February 2003 (17.02.2003) EP

(71) Applicant (for all designated States except US): **F. HOFF-
MANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse
124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALBERATI-GI-
ANI, Daniela** [IT/CH]; Kirchplatz 4, CH-4800 Zofingen
(CH). **CECCARELLI, Simona, Maria** [IT/CH]; Of-
fenburgerstrasse 29, CH-4057 Basel (CH). **PINARD,
Emmanuel** [FR/FR]; 7, rue de Pujo, F-68480 Linsdorf
(FR). **STALDER, Henri** [CH/CH]; St. Johannis-Ring 145,
CH-4056 Basel (CH).

(74) Agent: **POPPE, Regina**; Grenzacherstrasse 124,
CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES



(57) Abstract: The present invention relates to compounds of the general formula (I) wherein R¹ is lower alkyl, -(CH₂)_n-aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, -OCF₃, halogen, -NR'R'' or trifluoromethyl, or heteroaryl; R² is lower alkyl, -(CH₂)_n-aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, cyano, -NR'R'', hydroxy, or by a heteroaryl group, or is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl or halogen; R³ is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl; R⁴ is hydrogen or hydroxy; A is -S(O)₂- or -C(O)-; X, Y are independently from each other -CH₂- or -O-, with the proviso that X and Y are not simultaneously -O; R'R'' are independently from each other hydrogen, lower alkyl or -C(O)-lower alkyl; n is 0, 1 or 2; and to pharmaceutically


acceptable acid addition salts thereof. The compounds may be used for the treatment of psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.



WO 2004/072034 A1

Piperidine-benzenesulfonamide derivatives

The present invention relates to compounds of the general formula



wherein

- R^1 is lower alkyl, $-(CH_2)_n$ -aryl, unsubstituted or substituted by one or two
 5 substituents, selected from the group consisting of lower alkyl, lower alkoxy,
 $-OCF_3$, halogen, $-NR'R''$ or trifluoromethyl, or is heteroaryl;
- R^2 is lower alkyl, $-(CH_2)_n$ -aryl, unsubstituted or substituted by one or two
 substituents, selected from the group consisting of lower alkyl, lower alkoxy,
 halogen, trifluoromethyl, nitro, cyano, $-NR'R''$, hydroxy, or by a heteroaryl group,
 10 or is heteroaryl, unsubstituted or substituted by one or two substituents, selected
 from the group consisting of lower alkyl or halogen;
- R^3 is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl;
- R^4 is hydrogen or hydroxy;
- A is $-S(O)_2-$ or $-C(O)-$;
- 15 X,Y are independently from each other $-CH_2-$ or $-O-$, with the proviso that X and Y are
 not simultaneously $-O-$;
- $R'R''$ are independently from each other hydrogen, lower alkyl or $-C(O)$ -lower alkyl;
- n is 0, 1 or 2;

and to pharmaceutically acceptable acid addition salts thereof.

Furthermore, the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.

The present invention relates to compounds of general formula I, to pharmaceutical composition containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.

Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, *Neuron*, 28:325-33, 2000). For decades research has focused on the "dopaminergic hyperactivity" hypothesis which have led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., *Exp. Opin. Ther. Targets*, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al., *Exp. Opin. Ther. Patents*, 10(1): 75-98, 2000). This pharmacological approach poorly address negative and cognitive symptoms which are the best predictors of functional outcome (Sharma T., *Br.J. Psychiatry*, 174(suppl. 28): 44-51, 1999).

A complementary model of schizophrenia was proposed in the mid-1960' based upon the psychotomimetic action caused by the blockade of the glutamate system by compounds like phencyclidine (PCP) and related agents (ketamine) which are non-competitive NMDA receptor antagonists. Interestingly in healthy volunteers, PCP-induced psychotomimetic action incorporates positive and negative symptoms as well as cognitive dysfunction, thus closely resembling schizophrenia in patients (Javitt DC et al., *Biol. Psychiatry*, 45: 668-679, 1999). Furthermore transgenic mice expressing reduced levels of the NMDAR1 subunit displays behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., *Cell*, 98: 427-236, 1999).

Glutamate neurotransmission, in particular NMDA receptor activity, plays a critical role in synaptic plasticity, learning and memory, such as the NMDA receptors appears to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, *Nature*, 361: 31-39, 1993). Transgenic mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., *Natur*, 401- 63-69,

1999).

Thus, if a glutamate deficit is implicate in the pathophysiology of schizophrenia, enhancing glutamate transmission, in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.

5 The amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently
10 present at a more constant level and seems to modulate/control the receptor for its response to glutamate.

One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses. Neurotransmitter
15 transporters by removing neurotransmitters from the extracellular space, can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, *Trends in Pharm. Sci.*, 23(8): 367-373, 2002).

Glycine transporters, which form part of the sodium and chloride family of
20 neurotransmitter transporters, play an important role in the termination of post-synaptic glycinergic actions and maintenance of low extracellular glycine concentration by re-uptake of glycine into presynaptic nerve terminals and surrounding fine glial processes.

25 Two distinct glycine transporter genes have been cloned (GlyT-1 and GlyT-2) from mammalian brain, which give rise to two transporters with ~50 % amino acid sequence homology. GlyT-1 presents four isoforms arising from alternative splicing and alternative promoter usage (1a, 1b, 1c and 1d). Only two of these isoforms have been found in rodent brain (GlyT-1a and GlyT-1b). GlyT-2 also presents some degree of heterogeneity.
30 Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains. GlyT-1 is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS. GlyT-1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function
35 (Lopez-Corcuera B et al., *Mol. Mem. Biol.*, 18: 13-20, 2001). Thus, one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GlyT-1 transporter (Bergereon R. Et al., *Proc. Natl. Acad. Sci. USA*, 95: 15730-15734, 1998).

Glycine transporters inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders. The majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, *Exp. Opin. Ther. Patents*, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders
5 associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., *Prog. Neurobiol.*, 67: 173-202, 2002), autistic disorders (Carlsson ML, *J. Neural Trans.*, 105: 525-535, 1998), cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal,
10 including a human, attention deficit disorders and pain (Armer RE and Miller DJ, *Exp. Opin. Ther. Patents*, 11 (4): 563-572, 2001).

Thus, increasing activation of NMDA receptors via GlyT-1 inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive
15 processes are impaired, such as attention deficit disorders or Alzheimer's disease.

Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt-1 inhibition, their manufacture, medicaments based on a compound in accordance
20 with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

The preferred indications using the compounds of the present invention are
25 schizophrenia, cognitive impairment and Alzheimer's disease.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1 - 4 carbon atoms.

30 The term "halogen" denotes chlorine, iodine, fluorine and bromine.


The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined above, and which is attached via an oxygen atom.

The term "aryl" denotes a monovalent cyclic aromatic radical consisting of one or more fused rings, in which at least one ring is aromatic in nature, for example phenyl or naphthyl.

The term "heteroaryl" denotes a monovalent heterocyclic 5 or 6-membered aromatic radical, wherein the heteroatoms are selected from N, O or S, for example the groups thiophenyl, pyridinyl, pyrimidinyl, imidazolyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, pyrazolyl, pyrazinyl, benzo[1.3]dioxolyl, benzo{b}thiophenyl or benzotriazolyl,

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

Preferred are compounds of formula



wherein

R^1 is lower alkyl, benzyl or is phenyl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R^2 is lower alkyl, benzyl, thiophenyl or is phenyl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl, nitro, amino, hydroxy or $-NHC(O)-$ lower alkyl;

R^3 is pyridin-3-yl, pyridin-4-yl or is phenyl, unsubstituted or substituted by halogen or lower alkyl;

R^4 is hydrogen or hydroxy;

A is $-S(O)_2-$ or $-C(O)-$;

X,Y are independently from each other $-\text{CH}_2-$ or $-\text{O}-$, with the proviso that X and Y are not simultaneously $-\text{O}-$;

and pharmaceutically acceptable acid addition salts thereof.

Especially preferred compounds of the present application are those of formula I,
 5 wherein X and Y are both $-\text{CH}_2-$, A is $-\text{S}(\text{O})_2-$, R^3 is unsubstituted phenyl and R^4 is hydrogen, for example the following compounds:

(+/-)-3,4-dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide,
 (+/-)-4-methoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-
 10 yl]-benzenesulfonamide,
 (+/-)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide,
 15 (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide,
 (+/-)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-
 phenyl)-benzenesulfonamide or
 (+)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 20 benzenesulfonamide.

Further preferred are compounds, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydrogen, for example the following compounds:

(+/-)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide,
 (+/-)-4-fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide,
 25 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-
 trifluoromethyl-benzamide or
 (+/-)-N-(4-chloro-phenyl)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzamide.

A further preferred group of compounds are those, wherein X and Y are both $-\text{CH}_2-$,
 30 A is $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydroxy, for example the following compounds:

(+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-
 methoxy-benzamide,
 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-

methoxy-benzamide,
 (+/-)-4-fluoro-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-
 benzamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-methoxy-
 5 phenyl)-benzamide or
 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-N-*p*-tolyl-
 benzamide.

Further preferred are compounds, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{S}(\text{O})_2-$,
 R^3 is unsubstituted phenyl or phenyl, substituted by chloro, fluoro or methyl, and R^4 is
 10 hydroxy, for example the following compounds:

(+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-
 benzenesulfonamide,
 (+)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-
 benzenesulfonamide,
 15 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-
 methoxy-benzenesulfonamide,
 (+/-)-N-{*cis*-1-[2-(4-chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
 N-phenyl-benzenesulfonamide,
 (+/-)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
 20 N-phenyl-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-*o*-tolyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-
 benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-
 methoxy-benzenesulfonamide,
 25 (+/-)-N-(4-fluoro-phenyl)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-
 piperidin-4-yl}-4-methoxy-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-
 methoxy-phenyl)-benzenesulfonamide,
 (+/-)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
 30 N-(3-methoxy-phenyl)-benzenesulfonamide or
 (+/-)-N-[*trans*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-
 phenyl-benzenesulfonamide.

Further preferred are compounds, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{S}(\text{O})_2-$,
 R^3 is pyridin-3-yl or pyridin-4-yl and R^4 is hydroxy, for example the following
 35 compounds:

- (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide,
 5 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-
 10 trifluoromethyl-phenyl)-benzenesulfonamide or
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide.

Further preferred are compounds, wherein X is $-\text{CH}_2-$, Y is $-\text{O}-$, A is $-\text{S}(\text{O})_2-$, R^3 is unsubstituted phenyl and R^4 is hydroxy, for example the following compound:

- 15 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide.


Further preferred are compounds, wherein X is $-\text{CH}_2-$, Y is $-\text{O}-$, A is $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydroxy, for example the following compound:

- (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-
 20 piperidin-4-yl]-3-methoxy-benzamide.

- Preferred are further those compounds, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{C}(\text{O})-$ and R^3 is heteroaryl, unsubstituted or substituted by halogen or lower alkyl or compounds, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{C}(\text{O})-$, R^2 is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group
 25 consisting of lower alkyl or halogen, and R^4 is hydrogen.

The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises

a) reacting a compound of formula




- 9 -

with a compound of formula



in the presence of a base and/or a proton scavenger


to a compound of formula



5

wherein X, Y, R¹, R² and R³ are as defined above, or

b) reacting a compound of formula




with a compound of formula



10

in the presence of a base and/or a proton scavenger


to a compound of formula



wherein X, Y, R¹, R² and R³ are as defined above, or

15 c) reacting a compound of formula


- 10 -



with a compound of formula




to a compound of formula




5

wherein A, X, Y, R¹, R² and R³ are as defined above, or

d) reacting a compound of formula




with a compound of formula



10

to a compound of formula



wherein A, X, Y, R¹, R² and R³ are as defined above, and


if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

The compounds of formula I may be prepared in accordance with process variant a) to d) and with the following schemes 1 to 7.

5 1. Preparation of compounds of formula I wherein R⁴ is hydrogen (scheme 1)

The compounds of the invention can be prepared by processes analogous to those established in the art.

Scheme 1



- 10 Compounds of formula I where R⁴ is hydrogen and A is an $-\text{S}(\text{O})_2-$ group are readily prepared by sulfonylation of the corresponding secondary amines using procedures established in the art, such as treating the amine with a sulfonyl chloride in the presence of a suitable base or proton scavenger (scheme 1, step C). Suitable amines include diisopropylethylamine, 4-dimethylaminopyridine, pyridine,

1,8-diazabicyclo[5.4.0]undec-7-ene and others. Proton scavengers include for example 1-methoxy-2-methyl-1-trimethylsilyloxy-propene.

Compounds of formula I where R^4 is hydrogen and A is a $-C(O)-$ group are readily prepared by acylation of the corresponding secondary amines using procedures
5 established in the art, such as treating the amine with an acyl chloride in the presence of a suitable base or proton scavenger (scheme 1, step D). Suitable amines include diisopropylethylamine, dimehtylaminopyridine, triethylamine, etc. Proton scavengers include for example 1-methoxy-2-methyl-1-trimethylsilyloxy-propene.


The precursor secondary amines are prepared by reductive amination of a ketone,
10 by reaction of the amine with the corresponding piperidone at 60 °C in ethanol in the presence of a stoichiometric quantity of titanium tetraisopropoxide, followed by reaction with sodium borohydride or sodium cyanoborohydride at room temperature (scheme 1, step B), or by reaction of the amine with the corresponding piperidone in the presence of an acid, as for example acetic acid, and sodium triacetoxyborohydride. Other reductive
15 amination procedures established in the art can also be used.

The precursor ketone is prepared by reductive amination of the corresponding cycloalkanone with 1,4-dioxo-8-azaspiro[4.5]decane, followed by hydrolysis of the acetal in acidic conditions as shown in scheme 1, step A. Both titanium promoted or acid
20 catalysed reductive amination is applicable. Only the *cis* arrangement is obtained. Deprotection of the acetal is obtained for example by treatment with concentrated chlorhydric acid in dioxane at the reflux temperature of the mixture.

Compounds of the invention can also be prepared by one of the above mentioned routes, using the methods and techniques of parallel solution phase synthesis.


2. Preparation of compounds of formula I wherein R⁴ is hydroxy (schemes 2-6)

Scheme 2



Compounds of formula I where R⁴ is a hydroxy group and A is -S(O)₂- or -C(O)- can be prepared by reacting N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylsulfonamides or N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylamides at -78°C in THF with one of the aryl lithium reagents R³-Li, which are either commercially available or accessible from the corresponding aryl halides, according to procedures established in the art (scheme 2, step F). With this protocol only the *cis* arrangement is obtained.

Scheme 3




The precursor N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylsulfonamides are obtained by oxidation of N-[1-(2-hydroxy-cycloalkyl)-piperidin-4-yl]-N-aryl-arylsulfonamides with one of the many procedures established in the art, for example with pyridine-sulfur trioxide complex in the presence of triethylamine and dimethylsulfoxide at room temperature. The same procedure applies for the synthesis of N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylamides (scheme 3, step E).

The precursor cyclic secondary alcohol can be prepared by reaction of a suitably functionalized amine with a cyclic epoxide (scheme 3, step D), for example by mixing the amine and the epoxide in ethanol at the reflux temperature of the solvent.

A suitably functionalized amine can be accessed by reaction of N-*tert*-

- 5 butoxycarbonyl-4-piperidone or N-benzyl-4-piperidinone with an amine R^1NH_2 (scheme 3, step A), followed by sulfonylation or acylation, as described above (scheme 3, step B). The protective group is then cleaved by acidic hydrolysis or hydrogenation according to procedures established in the art (scheme 3, step C).


Scheme 4



- Alternatively, a second synthetic route can be applied to the synthesis of N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylsulfonamides or N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylamides, as illustrated in scheme 4. 1-(2-Hydroxy-cyclohexyl)-piperidin-4-one is treated with an amine R^1NH_2 in the presence of titanium
- 15 tetraisopropoxide and sodium cyanoborohydride (scheme 4, step B). The resulting 2-(4-arylamino-piperidin-1-yl)-cyclohexanol is oxidized with pyridine-sulfur trioxide complex to the corresponding 2-(4-arylamino-piperidin-1-yl)-cyclohexanone (scheme 4, step C). This is either sulfonylated or acylated at the secondary amine as described above, yielding N-[1-(2-oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylsulfonamides or N-[1-(2-
- 20 oxo-cycloalkyl)-piperidin-4-yl]-N-aryl-arylamides (scheme 4, step D).


1-(2-Hydroxy-cyclohexyl)-piperidin-4-one is prepared by reaction of 1,4-dioxaspiro[4.5]decane with cyclohexene oxide, followed by hydrolysis of the acetal in acidic conditions as shown in scheme 4, step A.

Scheme 5



Suitably functionalized piperidines, such as those shown in scheme 3, can also be reacted with 1-aryl-cyclohexene oxide, as shown in scheme 5, to provide compounds of the invention in which the arrangement of substituents of the cycloalkane ring is *trans*.

Scheme 6




Moreover, suitably functionalized piperidines such as those shown in scheme 3, can also be reacted with (+/-)-3,7-dioxabicyclo[4.1.0]heptane (prepared as described in: Tchelitcheff P.; C.R.Hebd.Seances Acad.Sci.; 224; 1947; 1722) (scheme 6, step A), and the resulting alcohols oxidized to the corresponding ketones as described above (scheme 6, step B). Reaction of such ketones with aryl lithium reagents (in analogy to scheme 2, step F), provides compounds of the invention where X or Y is -O-.

3. Preparation of compounds, wherein R^2-R^4 , X and Y have the meaning as described above and R^1 is heteroaryl

Compounds of formula I where R^1 is an heteroaromatic ring and $A = CO$ are also prepared by acylation of the corresponding heteroaromatic amine with a suitable acyl chloride in the presence of a strong non-protic base, as for example 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine (BEMP). For purposes of facilitating purification of the reaction mixtures, also solid phase bound non-protic bases can be used, for example polystyrene-bound BEMP. Secondary heteroaromatic amines of the invention in which R^1 is an heteroaromatic ring, in particular an azine ring, are prepared by reacting the corresponding primary amine with a heteroaryl halide, preferably a heteroaryl iodide or bromide in the presence of a base and a catalytic quantity of a suitable palladium complex. The precursor primary amine can be prepared by reductive amination of the corresponding 4-piperidone with a NH_3 source, for example by reaction with ammonium formate in the presence of $Pd(0)$, or by other methods known in the art (Scheme 7).

Scheme 7



The conversion to a salt of compounds of formula I is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained

between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.

The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GlyT-1).

10 The compounds were investigated in accordance with the test given hereinafter.

Solutions and materials

DMEM complete medium: DMEM (Gibco Life-technologies), high glucose, Fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Geneticin 1 mg/ml (Gibco life technologies), Proline 19.8 mg/0.5 L of medium (Sigma).

Uptake buffer (UB): 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl₂, 2.5 mM KCl, 2.5 mM MgSO₄, 10 mM (+)D-glucose.

Chinese Hamster Ovary (CHO) cells stably transfected with hGlyT1b cDNA, clone A467-47.

Glycine uptake inhibition assay (hGlyT-1b)

On day 1 mammalian cells, (CHO), transfected with hGlyT-1b cDNA (clone A467-47), were plated at the density of 50,000 cells/well in complete DMEM medium in 96-well culture plates. On day 2, the medium was aspirated and the cells were washed twice with uptake buffer (UB). The cells were then incubated for 30 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine, (iii) a concentration of a potential inhibitor. A range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g. IC₅₀, the concentration of the competitor inhibiting glycine uptake of 50 %). A solution was then immediately added containing [³H]-glycine 60 nM (11-16 Ci/mmol) and 25 µM non-radioactive glycine. The cells were then incubated with gentle shaking for 30 min at 22-24 °C, after which the reaction was stopped by aspiration of the mixture and washing (three times) with ice-cold UB. The cells were lysed with scintillation liquid, shaken 3 hours and the radioactivity in the cells was counted using a scintillation counter.

The preferred compounds show an IC₅₀ (μM) at GlyT-1 in the range of 0.015 – 0.100, as seen in the table below:

Example	IC ₅₀ (μM)	Example	IC ₅₀ (μM)
1	0.048	108	0.04
3	0.094	109	0.073
11	0.056	110	0.076
17	0.049	111	0.068
22	0.083	112	0.061
34	0.098	114	0.066
35	0.066	115	0.071
67	0.099	120	0.091
69	0.029	121	0.071
75	0.068	123	0.095
96	0.049	125	0.096
98	0.033	139	0.044
99	0.028	141	0.1
100	0.015	142	0.063
102	0.092	144	0.082
105	0.084	159	0.068
107	0.083	163	0.085

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions,

emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
		5 mg	25 mg	100 mg	500 mg
	1. Compound of formula I	5	25	100	500
5	2. Lactose Anhydrous DTG	125	105	30	150
	3. Sta-Rx 1500	6	6	6	30
	4. Microcrystalline Cellulose	30	30	30	150
	5. Magnesium Stearate	1	1	1	1
	Total	167	167	167	831

10 Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50 °C.
3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

15

Capsule Formulation

<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
		5 mg	25 mg	100 mg	500 mg
	1. Compound of formula I	5	25	100	500
	2. Hydrous Lactose	159	123	148	---
20	3. Corn Starch	25	35	40	70
	4. Talc	10	15	10	25
	5. Magnesium Stearate	1	2	2	5
	Total	200	200	300	600

Manufacturing Procedure

- 25 1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Example 1

(+/-)-3,4-Dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound was prepared as illustrated in scheme 1.

- 5 (A) Preparation of (+/-)-*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-one. To a solution of 2-phenyl-cyclohexanone (46.0 g, 264 mmol) and 1,4-dioxo-8-aza-spiro[4,5]decane (31.5 g, 220 mmol) in toluene (380 ml), *p*-toluenesulphonic acid monohydrate (4.18 g, 22.0 mmol) was added and the mixture was heated to reflux in an apparatus equipped with a Dean-Stark trap for 24 h. The reaction mixture was then evaporated and the resulting
- 10 crude enamine dissolved in 1,2-dichloroethane (900 ml) and acetic acid (8.00 ml). To this solution, sodium triacetoxyborohydride (69.0 g, 308 mmol) was added in portion. After a total reaction time of 2.5 h, the reaction mixture was treated with 2N NaOH (250 ml) and extracted with dichloromethane. The pooled organic extracts were washed with brine, dried over magnesium sulphate, filtered and evaporated. Purification of the crude
- 15 product over a silica gel plug (10:1) with n-heptane/ethyl acetate 10:1 then n-heptane/ethyl acetate 9:1 and finally ethyl acetate as eluent provided (+/-)-8-(*cis*-2-phenyl-cyclohexyl)-1,4-dioxo-8-aza-spiro[4,5]decane (44.8 g, 68 %) as a yellow oil, MS (ISP): $m/e = 302.4$ ($M+H^+$).

- A solution of (+/-)-8-(*cis*-2-phenyl-cyclohexyl)-1,4-dioxo-8-aza-spiro[4,5]decane (44.8
- 20 g) in MeOH (100 ml) and 6N HCl (445 ml) was heated to reflux for 16 h. The reaction mixture was then made basic with solid sodium carbonate, extracted with dichloromethane, dried over sodium sulphate, filtered and evaporated. The crude product was purified by flash chromatography over silica gel with n-heptane as eluent. (+/-)-1-(*cis*-2-phenyl-cyclohexyl)-piperidin-4-one (28.8 g, 75 %) was obtained as a sticky
- 25 yellow oil, MS (ISP): $m/e = 258.3$ ($M+H^+$).

- (B) Reductive amination to (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine. A solution of (+/-)-*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-one (0.500 g, 1.94 mmol) and aniline (0.360 g, 3.88 mmol) in technical ethanol (3 ml) was treated with $Ti(OiPr)_4$ (1.10 g, 1.15 ml, 3.88 mmol). The resulting solution was warmed to 60°C and
- 30 stirred for 2.5 hours. After cooling to room temperature, sodium cyanoborohydride (0.244 g, 3.88 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with dichloromethane (40 ml) and treated under vigorous stirring with NaOH 5N (2 ml) and sodium sulphate (3.0 g). After 15 minutes, white solids separated from a clear solution, which was filtered and evaporated
- 35 to a crude oil. Purification was achieved by flash chromatography (20-70 % ether in

dichloromethane). The title amine (0.460 g, 70 %) was obtained as a deliquescent white solid, MS (ISP): $m/e = 335.2$ ($M+H^+$).

(C) Sulfonylation to (+/-)-3,4-dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide. A solution of (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (0.105 mg, 0.310 mmol) in dry pyridine (1.5 ml) and dichloromethane (1.0 ml) was treated with a solution of 3,4-dichloro-benzenesulfonyl chloride (0.131 mg, 0.530 mmol) in dichloromethane (1.0 ml), and stirred at room temperature for 24 h. The mixture was then diluted with dichloromethane and quenched with water and sodium hydroxide 1N (1.0 ml). The phases were separated and the aqueous phase extracted twice with dichloromethane. The combined organic phases were dried with anhydrous sodium sulphate, then concentrated to a crude residue. This was purified by flash chromatography on silica gel, eluting with ethyl acetate 10-30 % in heptane. The title compound of the example (0.158 g, 92 %) was obtained as an off-white solid, MS (ISP): $m/e = 543.3$ and 545.3 ($M+H^+$).

Example 2

(+/-)-3,4-Dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The compound of the example was prepared as for example 1 for steps (A) to (B). Step (C) was substituted by the following procedure:

(C) Acylation to (+/-)-3,4-dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide. A solution of (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (0.017 g, 0.050 mmol), dimethylaminopyridine (0.012 g, 0.010 mmol) and 1-methoxy-2-methyl-1-trimethylsiloxypropene (0.020 ml, 0.10 mmol) in dry tetrahydrofuran (0.5 ml) was treated with a solution of 3,4-dichlorobenzoyl chloride (16 mg, 0.075 mmol) in dry tetrahydrofuran (0.37 ml). The mixture was shaken on a Büchi Syncore Shaker for 20 h, then quenched with water (0.15 ml). The reaction mixture was then injected directly into a preparative HPLC column (YMC ODS-AQ; 50 x 20mm; 5 μ m; flow: 30 ml/min; run time: 5 min; gradient: 20-80 % acetonitrile in water; detection: light scattering). The title compound (7.0 mg, 28 %) was obtained as a white solid, MS (ISP): $m/e = 507.30$ ($M+H^+$).

Example 3

(+/-)-4-Methoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 535.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

5

Example 4

(+/-)-N-Phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-isobutyramide

The title compound, MS (ISP): $m/e = 405.6$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-
10 propanoyl chloride in step (C).

Example 5

(+/-)-3-Methoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

15 The title compound, MS (ISP): $m/e = 499.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3-methoxybenzoyl chloride in step (C).

Example 6

20 (+/-)-N-(3-Methoxy-phenyl)-2-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-acetamide

The title compound, MS (ISP): $m/e = 483.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted
25 with 2-phenyl-acetyl chloride in step (C).

Example 7

(+/-)-N-Phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 439.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-

(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzoyl chloride in step (C).

Example 8

(+/-)-N-(3-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- 5 The title compound, MS (ISP): $m/e = 469.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with benzoyl chloride in step (C).

Example 9

- 10 (+/-)-N-Benzyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 453.6$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using benzyl amine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with benzoyl chloride in step (C).

15

Example 10

(+/-)-N-Phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

- The title compound, MS (ISP): $m/e = 475.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzenesulfonyl
20 chloride in step (C).

Example 11

(+/-)-4-Methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

- The title compound, MS (ISP): $m/e = 505.3$ ($M+H^+$), was prepared as for example 1,
25 steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzenesulfonyl chloride in step (C).

Example 12

- (+/-)-N-(3-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
30 benzenesulfonamide

The title compound, MS (ISP): $m/e = 505.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-

methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzensulfonyl chloride in step (C).

Example 13

(+/-)-N-Benzyl-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
5 benzenesulfonamide

The title compound, MS (ISP): $m/e = 519.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using benzylamine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

10

Example 14

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 453.6$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with benzoyl
15 chloride in step (C).

Example 15

(+/-)-2-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 467.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 2-
20 methyl-benzoyl chloride in step (C).

Example 16

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-3-trifluoromethyl-benzamide

25 The title compound, MS (ISP): $m/e = 521.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 3-trifluoromethyl-benzoyl chloride in step (C).

Example 17

30 (+/-)-3-Methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 483.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

5

Example 18

(+/-)-4-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 467.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 4-methyl-benzoyl chloride in step (C).

10

Example 19

(+/-)-4-Chloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 487.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 4-chloro-benzoyl chloride in step (C).

15

Example 20

(+/-)-4-Methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 483.6$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 4-methoxy-benzoyl chloride in step (C).

20

Example 21

(+/-)-3,4-Dichloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 521.4, 523.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 3,4-dichloro-benzoyl chloride in step (C).

25

Example 22

(+/-)-4-Fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 471.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was then reacted with 4-fluoro-benzoyl chloride in step (C).

Example 23

(+/-)-N-(4-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 469.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with benzoyl chloride in step (C).

Example 24

(+/-)-N-(4-Methoxy-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 483.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 2-methyl-benzoyl chloride in step (C).

Example 25

(+/-)-N-(4-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethyl-benzamide

The title compound, MS (ISP): $m/e = 537.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-trifluoromethyl-benzoyl chloride in step (C).

Example 26

(+/-)-3-Methoxy-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 499.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

5

Example 27

(+/-)-N-(4-Methoxy-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 483.60$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then
10 reacted with 4-methyl-benzoyl chloride in step (C).

Example 28

(+/-)-4-Chloro-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

15 The title compound, MS (ISP): $m/e = 503.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-chloro-benzoyl chloride in step (C).

Example 29

20 (+/-)-3,4-Dichloro-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 537.4, 539.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then
25 reacted with 3,4-dichloro-benzoyl chloride in step (C).

Example 30

(+/-)-4-Fluoro-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 487.40$ ($M+H^+$), was prepared as for example 2,
30 steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-

- 29 -

methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-fluoro-benzoyl chloride in step (C).

Example 31

5 (+/-)-Thiophene-2-carboxylic acid (4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 475.40$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 2-thiophenecarbonyl chloride in step (C).

10

Example 32

(+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

15 The title compound, MS (ISP): $m/e = 473.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with benzoyl chloride in step (C).

Example 33

(+/-)-N-(4-Chloro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

20 The title compound, MS (ISP): $m/e = 487.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 2-methyl-benzoyl chloride in step (C).

Example 34

25 (+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethyl-benzamide

The title compound, MS (ISP): $m/e = 541.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-trifluoromethyl-benzoyl chloride in step (C).

Example 35

(+/-)-N-(4-Chloro-phenyl)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

5 The title compound, MS (ISP): $m/e = 503.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

Example 36

10 (+/-)-4-Chloro-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 507.5, 509.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-chloro-benzoyl chloride in step (C).

15

Example 37

(+/-)-N-(4-Chloro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

20 The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-methoxy-benzoyl chloride in step (C).

Example 38

(+/-)-3,4-Dichloro-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

25 The title compound, MS (ISP): $m/e = 507.5, 509.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3,4-dichloro-benzoyl chloride in step (C).

Example 39

(+/-)-N-(4-Chloro-phenyl)-4-fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

5 The title compound, MS (ISP): $m/e = 491.30$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-fluoro-benzoyl chloride in step (C).

Example 40

10 (+/-)-Thiophene-2-carboxylic acid (4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 479.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 2-thiophenecarbonyl chloride in step (C).

15

Example 41

(+/-)-3-Methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 519.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 3-methoxy-benzensulfonyl chloride in step (C).

Example 42

(+/-)-4-Chloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

Example 43

(+/-)-3,4-Dichloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 557.3, 559.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

Example 44

10 (+/-)-3,4-Dichloro-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 573.3, 575.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

15

Example 45

(+/-)-4-Chloro-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 543.3, 545.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

Example 46

(+/-)-N-(4-Chloro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 539.5 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

Example 47

(+/-)-Thiophene-2-sulfonic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amide

- The title compound, MS (ISP): $m/e = 495.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 2-thiophenyl-sulphonyl chloride in step (C).

Example 48

(+/-)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

- The title compound, MS (ISP): $m/e = 489.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with benzenesulfonyl chloride in step (C).

Example 49

- (+/-)-2-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

- The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 2-methyl-benzenesulfonyl chloride in step (C).

Example 50

(+/-)-4-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzenesulfonamide

- The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 4-methyl-benzenesulfonyl chloride in step (C).

Example 51

- (+/-)-N-(4-Chloro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzensulfonyl chloride in step (C).

5

Example 52

(+/-)-N-(4-Chloro-phenyl)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3-methoxy-benzensulfonyl chloride in step (C).

10

Example 53

(+/-)-N-(4-Chloro-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

15

Example 54

(+/-)-3,4-Dichloro-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 577.1, 579.1$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

20

Example 55

(+/-)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-3-trifluoromethyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 557.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-

30

phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 3-trifluoromethyl-benzensulfonyl chloride in step (C).

Example 56

(+/-)-N-(4-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
5 benzenesulfonamide

The title compound, MS (ISP): $m/e = 505.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzenesulfonyl chloride in step (C).

10

Example 57

(+/-)-N-(4-Methoxy-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
benzenesulfonamide

The title compound, MS (ISP): $m/e = 519.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-
15 methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzensulfonyl chloride in step (C).

Example 58

(+/-)-N-(4-Methoxy-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 519.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

Example 59

25 (+/-)-4-Chloro-N-(4-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted
30 with 4-chloro-benzensulfonyl chloride in step (C).

Example 60

(+/-)-N-(3,4-Dichloro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 573.3, 575.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3,4-dichloro-aniline, and yielded (+/-)-(3,4-dichloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

Example 61

10 (+/-)-4-Chloro-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.5 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

15

Example 62

(+/-)-N-(3-Methoxy-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 519.5 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

Example 63

(+/-)-3,4-Dichloro-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 573.3, 575.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

Example 64

(+/-)-4-Fluoro-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-fluoro-benzensulfonyl chloride in step (C).

Example 65

10 (+/-)-N-(3-Methoxy-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 519.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzensulfonyl chloride in step (C).

15

Example 66

(+/-)-4-Chloro-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 527.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

Example 67

(+/-)-N-(4-Fluoro-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 507.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

Example 68

(+/-)-3,4-Dichloro-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 561.4, 563.4 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

Example 69

10 (+/-)-N-(4-Fluoro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 523.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

15

Example 70

(+/-)-4-Fluoro-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 511.4 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-fluoro-benzensulfonyl chloride in step (C).

Example 71

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 493.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzenesulfonyl chloride in step (C).

Example 72

(+/-)-N-(4-Fluoro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 507.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzensulfonyl chloride in step (C).

Example 73

10 (+/-)-4-Chloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 577.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

15

Example 74

(+/-)-4-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 557.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

Example 75

(+/-)-4-Methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 573.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

Example 76

(+/-)-4-Fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 561.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with 4-fluoro-benzensulfonyl chloride in step (C).

Example 77

10 (+/-)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 543.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with benzenesulfonyl chloride in step (C).

15

Example 78

(+/-)-2-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 557.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-trifluoromethyl-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was reacted with 2-methyl-benzensulfonyl chloride in step (C).

Example 79

(+/-)-4-Chloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

Example 80

(+/-)-4-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 4-methyl-benzensulfonyl chloride in step (C).

Example 81

10 (+/-)-3,4-Dichloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 557.4, 559.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 3,4-dichloro-benzensulfonyl chloride in step (C).

15 Example 82

(+/-)-4-Methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 519.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 4-methoxy-benzensulfonyl chloride in step (C).

Example 83

(+/-)-4-Fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

25 The title compound, MS (ISP): $m/e = 507.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 4-fluoro-benzensulfonyl chloride in step (C).

Example 84

30 (+/-)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 489.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with benzenesulfonyl chloride in step (C).

5

Example 85

(+/-)-2-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*o*-tolyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using *o*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*o*-tolyl-amine, which was reacted with 2-methyl-benzenesulfonyl chloride in step (C).

10

Example 86

(+/-)-4-Chloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 509.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chloro-benzenesulfonyl chloride in step (C).

15

Example 87

(+/-)-4-Methyl-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 489.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methyl-benzenesulfonyl chloride in step (C).

25

Example 88

(+/-)-4-Fluoro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 493.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-

30

(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-fluorobenzenesulfonyl chloride in step (C).

Example 89

5 (+/-)-2-Methyl-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 489.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methylbenzenesulfonyl chloride in step (C).

10

Example 90

(+/-)-N-Benzyl-4-chloro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

15 The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using benzylamine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chlorobenzenesulfonyl chloride in step (C).

Example 91

(+/-)-N-Benzyl-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

20 The title compound, MS (ISP): $m/e = 503.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using benzylamine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methylbenzenesulfonyl chloride in step (C).

Example 92

25 (+/-)-N-(3,4-Dichloro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 557.4, 559.4$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3,4-dichloro-aniline, and yielded (+/-)-(3,4-dichloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was
30 reacted with 2-methyl-benzenesulfonyl chloride in step (C).

Example 93

(+/-)-4-Chloro-N-(3,4-dichloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 577.2, 579.2 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3,4-dichloro-aniline, and yielded (+/-)-(3,4-dichloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-chloro-benzensulfonyl chloride in step (C).

Example 94

(+/-)-4-Nitro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 520.3 (M+H^+)$, was prepared as for example 1, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-Phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-nitro-benzensulfonyl chloride in step (C).

Example 95

(+/-)-4-Amino-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 490.3 (M+H^+)$, was prepared by hydrogenation of (+/-)-4-nitro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide according to the following procedure.

(+/-)-4-Nitro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide (0.05 g, 0.096 mmol) was suspended in isopropanol (3 ml) and the mixture was purged with argon. Palladium hydroxide on charcoal was added to the suspension, which was then put under an hydrogen atmosphere and stirred at room temperature for 20 h. The catalyst was then filtered off and the solvent was evaporated, leaving the title compound as a white foamy solid (0.039 g, 82 %).

Example 96

(+)-4-Methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 505.5 (M+H^+)$, was obtained by chromatographic separation of (+/-)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-

yl]-benzenesulfonamide on a chiral column [Chiralpak AD, solution: ethanol (2 ml)/heptane (3 ml), elution: 5% isopropanol in heptane, flux: 35 ml/min, wavelength: 245 nm, retention time: 26.73 min.]

Example 97

5 (-)-4-Methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 505.5$ ($M+H^+$), was obtained by chromatographic separation of (+/-)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide on a chiral column [Chiralpak AD, solution: ethanol (2 ml)/heptane (3 ml), elution: 5% isopropanol in heptane, flux: 35 ml/min, wavelength: 245 nm, retention time: 32.5 min.]

Example 98

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide

15 The title compound was prepared as illustrated in schemes 2 and 3.

(A) Reductive amination to 4-(4-fluoro-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester. To a solution of 1-Boc-4-piperidone (10.0 g, 50.0 mmol) in 1,2-dichloroethane (100 ml) was added 4-fluoroaniline (5.60 g, 50.0 mmol), acetic acid (6.20 ml, 103 mmol) and sodium triacetoxyborohydride (16.8 g, 75.3 mmol). After stirring at room temperature for 18 hours, the reaction mixture was quenched with sodium hydroxide 1N (200 ml). The aqueous phase was extracted with dichloromethane, the combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The residue was taken up in ether to provide a precipitate. Filtration led to 4-(4-fluoro-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester (11.1 g, 75 %) as an off white solid, MS (ISP): $m/e = 295.3$ ($M+H^+$).

(B) Acylation to 4-[(4-fluoro-phenyl)-(3-methoxy-benzoyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester. To a solution of 4-(4-fluoro-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester (5.0 g, 17 mmol) in dichloromethane (60 ml) was added triethylamine (5.9 ml, 42 mmol), 4-dimethylaminopyridine (0.21 g, 1.7 mmol) and 3-methoxybenzoyl chloride (3.5 g, 20 mmol). After stirring at room temperature for 20 hours, the reaction mixture was quenched with saturated sodium hydrogencarbonate (50 ml). The aqueous phase was extracted with dichloromethane, the combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo.

The residue was taken in ether to provide a precipitate. Filtration led to 4-[(4-fluoro-phenyl)-(3-methoxy-benzoyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester (6.2 g, 84 %) as a white solid, MS (ISP): $m/e = 429.3$ ($M+H^+$).

(C) Deprotection to N-(4-fluoro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide. To a
5 0°C solution of 4-[(4-fluoro-phenyl)-(3-methoxy-benzoyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester (6.0 g, 14 mmol) in dichloromethane (60 ml) was added trifluoroacetic acid (11 ml, 141 mmol). After 1.5 hours stirring at room temperature, the reaction mixture was concentrated in vacuo. The residue was taken in dichloromethane and sodium hydroxyde (1N). The aqueous phase was extracted with dichloromethane,
10 the combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The residue was taken in ether to provide a precipitate. Filtration led to N-(4-fluoro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide (4.2 g, 90%) as a light yellow solid, MS (ISP): $m/e = 329.3$ ($M+H^+$).

(D) Preparation of (+/-)-N-(4-fluoro-phenyl)-N-[*trans*-1-(2-hydroxy-cyclohexyl)-
15 piperidin-4-yl]-3-methoxy-benzamide. To a solution of N-(4-fluoro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide (3.0 g, 9.1 mmol) in ethanol (30 ml) was added cyclohexene oxide (0.90 ml, 9.1 mmol). The reaction mixture was refluxed for 44 hours then cooled to room temperature and concentrated. The residue was boiled in ether for 1 hour then cooled to room temperature to provide a precipitate. Filtration led to (+/-)-N-
20 (4-fluoro-phenyl)-N-[*trans*-1-(2-hydroxy-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide (3.5 g, 90%) as a light yellow solid, MS (ISP): $m/e = 427.3$ ($M+H^+$).

(E) Oxidation to (+/-)-N-(4-fluoro-phenyl)-3-methoxy-N-[1-(2-oxo-cyclohexyl)-
piperidin-4-yl]-benzamide. To a solution of (+/-)-N-(4-fluoro-phenyl)-N-[*trans*-1-(2-
25 hydroxy-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide (1.0 g, 2.3 mmol) in dichloromethane (6.0 ml) and dimethylsulfoxide (6.0 ml) was added triethylamine (1.6 ml, 12 mmol). The reaction mixture was cooled to 0 °C and a solution of sulfur trioxide-pyridine complex (1.1 g, 7.0 mmol) in dimethylsulfoxide was added dropwise. After 2 hours stirring at RT, the reaction mixture was poured into water and dichloromethane. The aqueous phase was extracted with dichloromethane, the combined organic layers
30 were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The residue was chromatographed over silica gel (CH_2Cl_2 -MeOH 97:3) to provide (+/-)-N-(4-fluoro-phenyl)-3-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzamide (0.82g, 83%) as a white solid, MS (ISP): $m/e = 425.3$ ($M+H^+$).

(F) Preparation of (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-
35 cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide. To a -78°C solution of (+/-)-N-(4-fluoro-phenyl)-3-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzamide (0.13 g,

0.30 mmol) in tetrahydrofuran (2.5 ml) was added phenyl lithium (1.7 M solution in cyclohexane/ether, 0.18 ml, 0.30 mmol,). After 40 min. stirring at -78°C , the reaction mixture was quenched with saturated ammonium chloride (5 ml) and the aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The residue was chromatographed over silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1) to provide (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide (0.050 g, 34 %) as a white foam, MS (ISP): $m/e = 503.4$ ($\text{M}+\text{H}^+$).

Example 99

(+/-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The title compound was prepared according to the procedure illustrated in schemes 2 and 4.

(A) Preparation of (+/-)-*trans*-1-(2-hydroxy-cyclohexyl)-piperidin-4-one. To a solution of 1,4-dioxo-8-azaspiro[4,5]decane (14.7 g, 100 mmol) in ethanol (75 ml) was added cyclohexene oxide (10.0 g, 100 mmol). The reaction mixture was refluxed for 40 hours then cooled to room temperature and concentrated. The residue was chromatographed over silica gel (hexane/ethylacetate 4:1) to provide (+/-)-*trans*-2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-cyclohexanol (22.1 g, 91 %) as a white solid, MS (ISP): $m/e = 241.2$ (M^+).

A solution of (+/-)-*trans*-2-(1,4-dioxo-8-aza-spiro[4.5]dec-8-yl)-cyclohexanol (1.50 g, 6.25 mmol) in dioxane (45 ml) was treated with 5N hydrogen chloride (10 ml). The mixture was warmed to 105°C and stirred for 4 h. After cooling to room temperature, water (9 ml) was added to the mixture, which was then basified to pH 14 by slow addition of 5N sodium hydroxide. The mixture was then extracted three times with ethyl acetate and the combined organic extracts were dried with anhydrous sodium sulphate and concentrated. The residual oil was purified by flash chromatography on silica gel, eluting with methanol 0-5 % in dichloromethane. (+/-)-*trans*-1-(2-Hydroxy-cyclohexyl)-piperidin-4-one (0.830 g, 68 %) was obtained as a white solid, MS (ISP): $m/e = 198.3$ ($\text{M}+\text{H}^+$).

(B) Reductive amination to (+/-)-*trans*-2-(4-phenylamino-piperidin-1-yl)-cyclohexanol. A solution of (+/-)-*trans*-1-(2-hydroxy-cyclohexyl)-piperidin-4-one (0.68, 3.4 mmol) in ethanol (4 ml) was treated with aniline (0.32 g, 3.4 mmol) and titanium tetrakisopropoxide (1.2 g, 4.1 mmol). The mixture was warmed to 38°C and stirred for 15 h. After cooling to 0°C by means of an ice/water bath, sodium borohydride (0.19 g, 5.1 mmol) was added in portions, whereupon vigorous hydrogen evolution took place. The

resulting slurry was diluted with ethanol (4 ml) and stirred at room temperature for 3 h. The reaction was further diluted with ethanol and quenched with 1N sodium hydroxide. The two phases were separated and the aqueous phase was extracted with dichloromethane. The combined organic extracts were dried with anhydrous sodium sulphate and concentrated. The residue was purified by flash chromatography on a silica gel column and eluted with methanol 0-10 % in dichloromethane. (+/-)-*trans*-2-(4-Phenylamino-piperidin-1-yl)-cyclohexanol (0.50 g, 53 %) was obtained as a white solid, MS (ISP): $m/e = 275.4$ ($M+H^+$)

(C) Oxidation to (+/-)-2-(4-phenylamino-piperidin-1-yl)-cyclohexanone. A solution of (+/-)-*trans*-2-(4-phenylamino-piperidin-1-yl)-cyclohexanol (0.22 g, 0.81 mmol) in dry dimethylsulfoxide (4.8 ml) was treated with triethylamine (0.41 g, 4.1 mmol). A solution of pyridine-sulfur trioxide complex (0.39 g, 2.4 mmol), which had been dried for one night in a vacuum pump, in dry dimethylsulfoxide (1.9 ml) was added dropwise to the mixture over 3 min. The solution was stirred at room temperature for 1 h, then quenched with water (50 ml). The mixture was extracted four times with ethyl acetate (4 x 20 ml). The combined organic phases were washed twice with water (2 x 20 ml), then dried with anhydrous sodium sulphate and concentrated to a colorless oil. Purification was achieved by chromatography on silica gel, eluting with methanol 0-10 % in dichloromethane. (+/-)-2-(4-Phenylamino-piperidin-1-yl)-cyclohexanone (0.12 g, 53 %) was obtained as an off-white solid, MS (ISP): $m/e = 273.4$ ($M+H^+$).

(D) Sulphonylation to (+/-)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide. (+/-)-2-(4-Phenylamino-piperidin-1-yl)-cyclohexanone was sulphonylated with 4-methoxy-benzensulphonyl chloride, as in example 1, step (C). (+/-)-4-Methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide, MS(ISP): $m/e = 443.5$ ($M+H^+$), was obtained as a white foamy solid.

(F) Preparation of (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide. A solution of bromobenzene (0.16 g, 1.0 mmol) in dry tetrahydrofuran (2.1 ml) was cooled to -70°C and a solution of butyl lithium 1.6 M in hexanes (0.65 ml, 1.0 mmol) was added dropwise. The resulting solution was stirred at -70°C for 1 h, then treated with a solution of (+/-)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide (0.12 mg, 0.26 mmol) in dry tetrahydrofuran (2.1 ml). The reaction mixture was stirred at -70°C for 1 h, then warmed slowly to room temperature and stirred for 10 min. After cooling to -78°C , the reaction was quenched with 20 % ammonium chloride (3.4 ml). The two phases were separated, and the aqueous phase extracted twice with ethyl acetate. The combined organic extracts were dried with anhydrous sodium sulphate and concentrated. The residue was purified by flash chromatography on silica gel, eluting

with methanol 0-5 % in dichloromethane. (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide, MS(ISP): m/e 521.5 ($M+H^+$), was obtained as a white foamy solid (0.093 g, 69%).

Example 100

- 5 (+)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): m/e = 521.5 ($M+H^+$), was obtained by chromatographic separation of (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide on a chiral column [Chiralpak AD, solution:
10 ethanol (2 ml)/heptane (3 ml), elution: 10% ethanol in heptane, flux: 35 ml/min, wavelength: 245 nm, retention time: 29.64 min.].

Example 101

(-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

- 15 The title compound, MS (ISP): m/e = 521.5 ($M+H^+$), was obtained by chromatographic separation of (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide on a chiral column [Chiralpak AD, solution: ethanol (2 ml)/heptane (3 ml), elution: 10% ethanol in heptane, flux: 35 ml/min, wavelength: 245 nm, retention time: 39.56 min.].

- 20 Example 102

(+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

- The title compound, MS (ISP): m/e = 555.3 ($M+H^+$), was prepared as for example 99, steps (A) to (F). Step (B) was performed using 4-chloro-aniline, and yielded (+/-)-*trans*-
25 2-[4-(4-chloro-phenylamino)-piperidin-1-yl]-cyclohexanol, which was oxidized to (+/-)-2-[4-(4-chloro-phenylamino)-piperidin-1-yl]-cyclohexanone in step (C). This was then reacted with 4-methoxy-benzensulfonyl chloride in step (D), yielding (+/-)-N-(4-chloro-phenyl)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide. The final step (F) was performed with bromobenzene.

- 30 Example 103

(+/-)-N-(4-Chloro-phenyl)-N-{*cis*-1-[2-(4-chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 589.3$ ($M+H^+$), was prepared as for example 102, steps (A) to (F). The final step (F) was performed with 4-bromo-chlorobenzene.

Example 104

(+/-)-N-(4-Chloro-phenyl)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-
5 piperidin-4-yl]-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 573.3$ ($M+H^+$), was prepared as for example 102, steps (A) to (F). The final step (F) was performed with 4-bromo-fluorobenzene.

Example 105

(+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-
10 yl]-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 556.3$ ($M+H^+$), was prepared as for example 102, steps (A) to (F). The final step (F) was performed with 3-bromo-pyridine.

Example 106

(+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-Hydroxy-2-*o*-tolyl-cyclohexyl)-piperidin-4-yl]-
15 4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 569.4$ ($M+H^+$), was prepared as for example 102, steps (A) to (F). The final step (F) was performed with 2-bromo-toluene.

Example 107

(+/-)-N-{*cis*-1-[2-(4-Chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
20 N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 555.3$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). The final step (F) was performed with 4-bromo-chlorobenzene.

Example 108

(+/-)-N-{*cis*-1-[2-(4-Fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
25 N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.4$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). The final step (F) was performed with 4-bromo-fluorobenzene.

Example 109

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 522.4$ ($M+H^+$), was prepared as for example 99,
5 steps (A) to (F). The final step (F) was performed with 4-bromo-pyridine.

Example 110

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 522.4$ ($M+H^+$), was prepared as for example 99,
10 steps (A) to (F). The final step (F) was performed with 3-bromo-pyridine.

Example 111

(+/-)-N-[*cis*-1-(2-Hydroxy-2-*o*-tolyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 535.4$ ($M+H^+$), was prepared as for example 99,
15 steps (A) to (F). The final step (F) was performed with 2-bromo-toluene.

Example 112

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.4$ ($M+H^+$), was prepared as for example 99,
20 steps (A) to (F). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-*trans*-2-[4-(4-fluoro-phenylamino)-piperidin-1-yl]-cyclohexanol, which was oxidized to (+/-)-2-[4-(4-fluoro-phenylamino)-piperidin-1-yl]-cyclohexanone in step (C). This was then reacted with 4-methoxy-benzensulfonyl chloride in step (D), yielding (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide. The
25 final step (F) was performed with bromobenzene.

Example 113

(+/-)-N-{*cis*-1-[2-(4-Chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-N-(4-fluoro-phenyl)-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 573.3$ ($M+H^+$), was prepared as for example 112, steps (A) to (F). The final step (F) was performed with 4-bromo-chlorobenzene.

Example 114

5 (+/-)-N-(4-Fluoro-phenyl)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 557.3$ ($M+H^+$), was prepared as for example 112, steps (A) to (F). The final step (F) was performed with 4-bromo-fluorobenzene.

Example 115

10 (+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 540.4$ ($M+H^+$), was prepared as for example 112, steps (A) to (F). The final step (F) was performed with 4-bromo-pyridine.

Example 116

15 (+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

The title compound, MS (ISP): $m/e = 540.4$ ($M+H^+$), was prepared as for example 112, steps (A) to (F). The final step (F) was performed with 3-bromo-pyridine.

Example 117

20 (+/-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 589.4$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). Step (B) was performed using 4-trifluoromethyl-aniline, and yielded (+/-)-*trans*-2-[4-(4-trifluoromethyl-phenylamino)-piperidin-1-yl]-cyclohexanol, which was oxidized to (+/-)-2-[4-(4-trifluoromethyl-phenylamino)-piperidin-1-yl]-cyclohexanone in step (C). This was then reacted with 4-methoxy-benzensulfonyl chloride in step (D), yielding (+/-)-N-(4-trifluoromethyl-phenyl)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide. The final step (F) was performed with bromobenzene.

Example 118

(+/-)-N-{*cis*-1-[2-(4-Chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 623.4$ ($M+H^+$), was prepared as for example 117,
5 steps (A) to (F). The final step (F) was performed with 4-bromo-chlorobenzene.

Example 119

(+/-)-N-{*cis*-1-[2-(4-Fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 607.3$ ($M+H^+$), was prepared as for example 117,
10 steps (A) to (F). The final step (F) was performed with 4-bromo-fluorobenzene.

Example 120

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 590.40$ ($M+H^+$), was prepared as for example 117,
15 steps (A) to (F). The final step (F) was performed with 4-bromo-pyridine.

Example 121

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 590.40$ ($M+H^+$), was prepared as for example 117,
20 steps (A) to (F). The final step (F) was performed with 3-bromo-pyridine.

Example 122

(+/-)-N-[*cis*-1-(2-Hydroxy-2-o-tolyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 603.4$ ($M+H^+$), was prepared as for example 117,
25 steps (A) to (F). The final step (F) was performed with 2-bromo-toluene.

Example 123

(+/-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 551.4$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-*trans*-2-[4-(3-methoxy-phenylamino)-piperidin-1-yl]-cyclohexanol, which was oxidized to (+/-)-2-[4-(3-methoxy-phenylamino)-piperidin-1-yl]-cyclohexanone in step (C). This
5 was then reacted with 4-methoxy-benzenesulfonyl chloride in step (D), yielding (+/-)-N-(3-methoxy-phenyl)-4-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide. The final step (F) was performed with bromobenzene.

Example 124

(+/-)-N-{*cis*-1-[2-(4-Chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
10 N-(3-methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 585.3$ ($M+H^+$), was prepared as for example 123, steps (A) to (F). The final step (F) was performed using 4-chloro-bromobenzene.

Example 125

(+/-)-N-{*cis*-1-[2-(4-Fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-
15 N-(3-methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 569.4$ ($M+H^+$), was prepared as for example 123, steps (A) to (F). The final step (F) was performed using 4-fluoro-bromobenzene.

Example 126

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-
20 methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 552.4$ ($M+H^+$), was prepared as for example 123, steps (A) to (F). The final step (F) was performed using 4-bromopyridine.

Example 127

(+/-)-N-[*cis*-1-(2-Hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-
25 methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 552.4$ ($M+H^+$), was prepared as for example 124, steps (A) to (F). The final step (F) was performed using 3-bromopyridine.

Example 128

(+/-)-4-Chloro-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

5 The title compound, MS (ISP): $m/e = 525.3$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). Step (D) was performed using 4-chloro-benzenesulphonyl chloride, and yielded (+/-)-4-chloro-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzensulfonamide. The final step (F) was performed with bromobenzene.

Example 129

10 (+/-)-4-Chloro-N-{*cis*-1-[2-(4-chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 559.30$ ($M+H^+$), was prepared as for example 128, steps (A) to (F). The final step (F) was performed using 4-chloro-bromobenzene.

Example 130

15 (+/-)-4-Chloro-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 543.4$ ($M+H^+$), was prepared as for example 128, steps (A) to (F). The final step (F) was performed using 4-fluoro-bromobenzene.

Example 131

20 (+/-)-4-Chloro-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 526.3$ ($M+H^+$), was prepared as for example 128, steps (A) to (F). The final step (F) was performed using 4-bromopyridine.

Example 132

25 (+/-)-4-Chloro-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 526.3$ ($M+H^+$), was prepared as for example 128, steps (A) to (F). The final step (F) was performed using 3-bromopyridine.

Example 133

(+/-)-4-Chloro-N-[*cis*-1-(2-Hydroxy-2-o-tolyl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 539.4$ ($M+H^+$), was prepared as for example 128, steps (A) to (F). The final step (F) was performed using 2-bromotoluene.

Example 134

(+/-)-3,4-Dichloro-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 559.3$ ($M+H^+$), was prepared as for example 99, steps (A) to (F). Step (D) was performed using 3,4-dichloro-benzenesulphonyl chloride, and yielded (+/-)-3,4-dichloro-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzensulfonamide. The final step (F) was performed with bromobenzene.

Example 135

(+/-)-3,4-Dichloro-N-{*cis*-1-[2-(4-chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 593.3$ ($M+H^+$), was prepared as for example 134, steps (A) to (F). The final step (F) was performed using 4-chloro-bromobenzene.

Example 136

(+/-)-3,4-Dichloro-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 577.3$ ($M+H^+$), was prepared as for example 134, steps (A) to (F). The final step (F) was performed using 4-fluoro-bromobenzene.

Example 137

(+/-)-3,4-Dichloro-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 560.2$ ($M+H^+$), was prepared as for example 135, steps (A) to (F). The final step (F) was performed using 3-bromopyridine.

Example 138

(+/-)-3,4-Dichloro-N-[*cis*-1-(2-Hydroxy-2-o-tolyl-cyclohexyl)-piperidin-4-yl]-N-phenyl-benzenesulfonamide

The title compound, MS (ISP): $m/e = 573.2$ ($M+H^+$), was prepared as for example 134, steps (A) to (F). The final step (F) was performed using 2-bromotoluene.

Example 139

(+/-)-N-(4-Chloro-phenyl)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-
5 3-methoxy-benzamide

The title compound, MS (ISP): $m/e = 519.4$ ($M+H^+$), white foam, was prepared as for example 98, steps (A) to (F). Step (A) was performed using 4-chloro-aniline, and yielded 4-(4-chloro-phenylamino)-piperidine-1-carboxylic acid *tert*-butyl ester which was acylated to 4-[(4-chloro-phenyl)-(3-methoxy-benzoyl)-amino]-piperidine-1-carboxylic
10 acid *tert*-butyl ester in step (B). This was then deprotected to N-(4-chloro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide (C), and reacted with cyclohexene oxide to give (+/-)-N-(4-chloro-phenyl)-N-[*trans*-1-(2-hydroxy-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide [step (D)]. Oxidation to (+/-)-N-(4-chloro-phenyl)-3-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzamide in step (E) and reaction with phenyl
15 lithium [step (F)] led to the title compound of the example.

Example 140

(+/-)-N-[*cis*-1-(2-Hydroxy-2-*o*-tolyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-methoxy-phenyl)-benzenesulfonamide

The title compound, MS (ISP): $m/e = 565.4$ ($M+H^+$), was prepared as for example 123,
20 steps (A) to (F). The final step (F) was performed using 2-bromotoluene.

Example 141

(+/-)-4-Fluoro-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 487.4$ ($M+H^+$), was prepared as for example 98,
25 steps (A) to (F). Step (A) was performed using 4-tolylamine, and yielded 4-*p*-Tolylamino-piperidine-1-carboxylic acid *tert*-butyl ester which was acylated with 4-fluorobenzoyl chloride to 4-[(4-fluoro-benzoyl)-*p*-tolyl-amino]-piperidine-1-carboxylic acid *tert*-butyl ester in step (B). This was then deprotected to 4-fluoro-N-piperidin-4-yl-N-*p*-tolyl-benzamide (C), and reacted with cyclohexene oxide to give (+/-)-4-fluoro-N-
30 [1-(2-hydroxy-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide [step (D)]. Oxidation to (+/-)-4-fluoro-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide in step (E) and reaction with phenyl lithium [step (F)] led to the title compound of the example.

Example 142

(+/-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-methoxy-phenyl)-benzamide

The title compound, MS (ISP): $m/e = 485.4$ ($M+H^+$), is prepared as for example 98, steps
5 (A) to (F). Step (A) is performed using 3-methoxy-aniline, and yields 4-(3-methoxy-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester which is acylated with benzoyl chloride to 4-[benzoyl-(3-methoxy-phenyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester (B). This is then deprotected to N-(3-methoxy-phenyl)-N-piperidin-4-yl-benzamide (C), and reacted with cyclohexene oxide to give (+/-)-N-[*trans*-1-(2-
10 hydroxy-cyclohexyl)-piperidin-4-yl]-N-(3-methoxy-phenyl)-benzamide [step (D)]. Oxidation to (+/-)-N-(3-methoxy-phenyl)-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-benzamide in step (E) and reaction with phenyl lithium [step (F)] leads to the title compound of the example.

Example 143

15 (+/-)-3-Methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 469.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

20

Example 144

(+/-)-N-[*cis*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 499.0$ ($M+H^+$), was prepared as for example 141, steps (A) to (F). Step (B) was performed using 3-methoxybenzoyl chloride, and yielded
25 4-[(3-methoxy-benzoyl)-*p*-tolyl-amino]-piperidine-1-carboxylic acid tert-butyl ester. This was then deprotected to 3-methoxy-N-piperidin-4-yl-N-*p*-tolyl-benzamide (step C), and reacted with cyclohexene oxide to give (+/-)-N-[*trans*-1-(2-hydroxy-cyclohexyl)-piperidin-4-yl]-3-methoxy-N-*p*-tolyl-benzamide [step (D)]. Oxidation to (+/-)-3-methoxy-N-[1-(2-oxo-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide in step (E) and
30 reaction with phenyl lithium [step (F)] led to the title compound of the example.

Example 145

(+/-)-4-Fluoro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 457.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-fluorobenzoyl chloride in step (C).

5

Example 146

(+/-)-N-Phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethylbenzamide

The title compound, MS (ISP): $m/e = 507.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-trifluorobenzoyl chloride in step (C).

10

Example 147

(+/-)-3-Methoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

15 The title compound, MS (ISP): $m/e = 499.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

Example 148

20 (+/-)-4-Fluoro-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 487.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then
25 reacted with 4-fluorobenzoyl chloride in step (C).

Example 149

(+/-)-N-(3-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethylbenzamide

The title compound, MS (ISP): $m/e = 537.4$ ($M+H^+$), was prepared as for example 2,
30 steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-

methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-trifluoro-benzoyl chloride in step (C).

Example 150

5 (+/-)-3,4-Dichloro-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 537.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3,4-dichloro-benzoyl chloride in step (C).

10

Example 151

(+/-)-N-(4-Fluoro-phenyl)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

15 The title compound, MS (ISP): $m/e = 487.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

Example 152

(+/-)-4-Fluoro-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

20 The title compound, MS (ISP): $m/e = 475.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 4-fluoro-benzoyl chloride in step (C).

Example 153

25 (+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethyl-benzamide

The title compound, MS (ISP): $m/e = 525.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then
30 reacted with 3-trifluoro-benzoyl chloride in step (C).

Example 154

(+/-)-3,4-Dichloro-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 525.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-fluoro-aniline, and yielded (+/-)-(4-fluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3,4-dichloro-benzoyl chloride in step (C).

Example 155

(+/-)-4-Fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-phenyl)-benzamide

The title compound, MS (ISP): $m/e = 525.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-trifluoro-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was then reacted with 4-fluoro-benzoyl chloride in step (C).

Example 156

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethyl-N-(3-trifluoromethyl-phenyl)-benzamide

The title compound, MS (ISP): $m/e = 575.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-trifluoro-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(3-trifluoromethyl-phenyl)-amine, which was then reacted with 3-trifluoro-benzoyl chloride in step (C).

Example 157

(+/-)-4-Hydroxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

A solution of (+/-)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide (0.047 g, 0.090 mmol) in dichloromethane (2 ml) was cooled to -78°C . Boron tribromide 1M in dichloromethane (0.30 ml, 0.30 mmol) was added dropwise at this temperature. The mixture was then warmed to room temperature and stirred for 5 hours. The reaction was quenched with sodium hydroxyde 1N and extracted three times with dichloromethane. The combined organic phases were dried with sodium sulfate and concentrated. The residue was purified via flash chromatography on silica gel

(dichloromethane/methanol/ammonia 110:10:1), yielding the title compound (0.029 mg, 63 %) as an off-white solid, MS (ISP): $m/e = 491.3$ ($M+H^+$).

Example 158

5 (+/-)-N-(4-{Phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-sulfamoyl}-phenyl)-acetamide

A solution of (+/-)-4-amino-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide (0.1 g, 0.2 mmol) in acetic acid (5 ml) was treated with acetic anhydride (1 ml) and stirred at room temperature for 1 h. The volatiles were evaporated and the residue was purified by flash chromatography on silica gel, eluting with
10 dichloromethane/methanol/ammonia 110:10:1. The product was crystallised from hexane/ether, yielding the title compound (0.06 g, 59%) as a white solid, MS (ISP): $m/e = 532.5$ ($M+H^+$).

Example 159

15 (+/-)-N-[*trans*-1-(2-Hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide

The compound of the example was prepared as illustrated in scheme 5.

To a solution of 4-methoxy-N-phenyl-N-piperidin-4-yl-benzenesulfonamide (1.1 g, 3.2 mmol) in ethanol (3.5 ml) was added (+/-)-1-phenyl-7-oxa-bicyclo[4.1.0]heptane (0.180 g, 1.06 mmol). The reaction mixture was refluxed for 48 hours then cooled to room
20 temperature and concentrated. The residue was chromatographed over silica gel ($CH_2Cl_2/MeOH$ 49:1) to provide (+/-)-N-[*trans*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide (65 mg, 6 %) as a white foam, MS (ISP): $m/e = 521.4$ ($M+H^+$).

Example 160

25 (+/-)-N-(4-Chloro-phenyl)-N-[*trans*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-benzamide

The title compound, MS (ISP): $m/e = 519.3$ ($M+H^+$), white foam, was prepared as for example 159 starting from N-(4-chloro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide.

30

Example 161

(+/-)-3-Methoxy-N-(3-methyl-butyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 463.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methyl-butylamine, and yielded (+/-)-(3-methyl-butyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was then reacted with 3-methoxy-benzoyl chloride in step (C).

5

Example 162

(+/-)-4-Methoxy-N-(3-methyl-butyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide

The title compound, MS (ISP): $m/e = 499.5$ ($M+H^+$), was prepared as for example 1, steps (A) to (C). Step (B) was performed using 3-methyl-butylamine, and yielded (+/-)-(3-methyl-butyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-methoxy-benzenesulfonyl chloride in step (C).

10

Example 163

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

15 The compound of the example was prepared as illustrated in scheme 2 and 6.

Preparation of N-(4-fluoro-phenyl)-4-methoxy-N-piperidin-4-yl-benzenesulfonamide. The title compound was prepared as in example 98, steps (A) to (C). Step (B) (acylation) was substituted by the following sulphonylation procedure. To a solution of 4-(4-fluoro-phenylamino)-piperidine-1-carboxylic acid tert-butyl ester (4.00 g, 13.6 mmol) in
20 dichloromethane (60 ml) and pyridine (32 ml) was added 4-methoxybenzenesulfonyl chloride (3.40 g, 16.3 mmol). After 40 hours stirring at room temperature, the reaction mixture was diluted with ethyl acetate (80 ml), washed with chlorhydric acid (2 x 50 ml, 0.5 N) and with saturated sodium hydrogencarbonate (50 ml), dried over sodium
25 sulphate, filtered and concentrated in vacuo. The residue was taken in ether to provide a precipitate. Filtration led to 4-[(4-fluoro-phenyl)-(4-methoxy-benzenesulfonyl)-amino]-piperidine-1-carboxylic acid tert-butyl ester (4.70 g, 74 %) as a off white solid, MS (ISP): $m/e = 465.2$ ($M+H^+$).

(A and B) Preparation of (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[1-(4-oxo-tetrahydro-pyran-3-yl)-piperidin-4-yl]-benzenesulfonamide and (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[1-(3-oxo-tetrahydro-pyran-4-yl)-piperidin-4-yl]-
30 benzenesulfonamide. To a solution of N-(4-fluoro-phenyl)-4-methoxy-N-piperidin-4-yl-benzenesulfonamide (7.60 g, 20.8 mmol) in ethanol (30 ml) was added rac-3,7-dioxabicyclo[4.1.0]heptane (2.50 g, 25.0 mmol). The reaction mixture was refluxed overnight, concentrated in vacuo and dissolved in dichloromethane (60 ml), dimethylsulfoxide (30

ml) and triethylamine (4.93 ml). The reaction mixture was cooled to 0°C and a solution of sulfur trioxide-pyridine complex (7.47 g, 21.1 mmol) in dimethylsulfoxide (30 ml) was added dropwise. After 2.5 hours stirring at RT, the reaction mixture was poured into water and dichloromethane. The aqueous phase was extracted with dichloromethane, the combined organic layers were dried over sodium sulphate, filtered and concentrated in vacuo. The residue was chromatographed over silica gel (heptane-ethylacetate 1:1) to provide N-(4-fluoro-phenyl)-4-methoxy-N-[1-(4-oxo-tetrahydro-pyran-3-yl)-piperidin-4-yl]-benzenesulfonamide (1.45 g, 15 %, first eluting compound) as a yellow oil, MS (ISP): $m/e = 463.2$ ($M+H^+$) and N-(4-fluoro-phenyl)-4-methoxy-N-[1-(3-oxo-tetrahydro-pyran-4-yl)-piperidin-4-yl]-benzenesulfonamide (0.120 g, 1.2 %, second eluting compound) as a yellow oil, MS (ISP): $m/e = 463.2$ ($M+H^+$).

(F) Preparation of (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide. To a -78°C solution of (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[1-(4-oxo-tetrahydro-pyran-3-yl)-piperidin-4-yl]-benzenesulfonamide (0.30 g, 0.65 mmol) in tetrahydrofuran (5 ml) was added phenyl lithium (1.7 M solution in cyclohexane/ether, 0.84 ml, 1.4 mmol). After 90 min. stirring at -78°C, the reaction mixture was quenched with saturated ammonium chloride (5 ml) and the aqueous phase was extracted with ethyl acetate. The combined organic layers were dried over sodium sulphate, filtered and concentrated in vacuo. The residue was chromatographed over silica gel (heptane/ethylacetate 7:3) to provide (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide (0.040 g, 12%) as a light yellow solid, MS (ISP): $m/e = 541.3$ ($M+H^+$).

Example 164

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(3-hydroxy-3-phenyl-tetrahydro-pyran-4-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide

The title compound of the example, MS (ISP): $m/e = 541.3$ ($M+H^+$), yellow solid, was prepared as for example 163, step (B), starting from N-(4-fluoro-phenyl)-4-methoxy-N-[1-(3-oxo-tetrahydro-pyran-4-yl)-piperidin-4-yl]-benzenesulfonamide.

Example 165

(+/-)-N-(4-Fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-3-methoxy-benzamide

The title compound of the example, MS (ISP): $m/e = 505.3$ ($M+H^+$), white foam, was prepared as for example 163, steps (A) to (F). N-(4-fluoro-phenyl)-3-methoxy-N-piperidin-4-yl-benzamide was used in step (A): oxidation provided (+/-)-N-(4-fluoro-

phenyl)-3-methoxy-N-[1-(4-oxo-tetrahydro-pyran-3-yl)-piperidin-4-yl]-benzamide, which was reacted with phenyl lithium in step (F).

Example 166

5 (+/-)-N-Phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-nicotinamide

The title compound, MS (ISP): $m/e = 440.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with nicotinoyl chloride
10 in step (C).

Example 167

(+/-)-Furan-2-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

15 The title compound, MS (ISP): $m/e = 429.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with furan-2-carbonyl chloride in step (C).

Example 168

20

(+/-)-Thiophene-2-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 445.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted thiophene-2-carbonyl
25 chloride in step (C).

Example 169

30 (+/-)-Thiophene-3-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 445.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with thiophene-3-carbonyl chloride in step (C).

35

Example 170

(+/-)-Isoxazole-5-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 430.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with isoxazole-5-carbonyl chloride in step (C).

5

Example 171

(+/-)-5-Methyl-isoxazole-3-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 444.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 5-methyl-isoxazole-3-carbonyl chloride in step (C).

10

Example 172

15 (+/-)-2,5-Dimethyl-2H-pyrazole-3-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 457.5$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2,5-dimethyl-2H-pyrazole-3-carbonyl chloride in step (C).

20

Example 173

(+/-)-Pyrazine-2-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 441.7$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with pyrazine-2-carbonyl chloride in step (C).

25

Example 174

(+/-)-2-Methyl-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

30 The title compound, MS (ISP): $m/e = 453.8$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzoyl chloride in step (C).

- 67 -

Example 175

(+/-)-Benzo[1,3]dioxole-5-carboxylic acid phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

- 5 The title compound, MS (ISP): $m/e = 483.8$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using aniline, and yielded (+/-)-phenyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzo[1,3]dioxole-5-carbonyl chloride in step (C).

Example 176

- 10 (+/-)-N-(3,5-Dimethyl-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 467.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3,5-dimethylaniline, and yielded (+/-)-(3,5-dimethyl-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was
15 reacted with benzoyl chloride in step (C).

Example 177

(+/-)-4-Dimethylamino-N-(3,5-dimethyl-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- The title compound, MS (ISP): $m/e = 510.3$ ($M+H^+$), was prepared as for example 2,
20 steps (A) to (C). Step (B) was performed using 3,5-dimethylaniline, and yielded (+/-)-(3,5-dimethyl-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-dimethylamino benzoyl chloride in step (C).

Example 178

(+/-)-3-Methoxy-N-phenethyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
25 benzamide

The title compound, MS (ISP): $m/e = 497.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using phenethylamine, and yielded (+/-)-phenethyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3-methoxy benzoyl chloride in step (C).

Example 179

(+/-)-3,4-Dimethoxy-N-phenethyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

5 The title compound, MS (ISP): $m/e = 527.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using phenethylamine, and yielded (+/-)-phenethyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dimethoxy benzoyl chloride in step (C).

Example 180

10 (+/-)-N-Benzyl-4-dimethylamino-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 496.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using benzylamine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-dimethylamino benzoyl chloride in step (C).

15

Example 181

(+/-)-N-Benzyl-3,4-dimethoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

20 The title compound, MS (ISP): $m/e = 513.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using benzylamine, and yielded (+/-)-benzyl-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dimethoxy benzoyl chloride in step (C).

Example 182

(+/-)-N-(3,5-Difluoro-phenyl)-2,5-difluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

25 The title compound, MS (ISP): $m/e = 511.2$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3,5-difluoroaniline, and yielded (+/-)-(3,5-difluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2,5-difluoro benzoyl chloride in step (C).

Example 183

N-(3,5-Difluoro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- 5 The title compound, MS (ISP): $m/e = 489.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3,5-difluoroaniline, and yielded (+/-)-(3,5-difluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzoyl chloride in step (C).

Example 184

- 10 (+/-)-2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid (3,5-difluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 507.2$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3,5-difluoroaniline, and yielded (+/-)-(3,5-difluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was
15 reacted with 2-ethyl-5-methyl-2H-pyrazole-3-carbonyl chloride in step (C).

Example 185

(+/-)-Benzo[1,3]dioxole-5-carboxylic acid (4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

- The title compound, MS (ISP): $m/e = 517.2$ ($M+H^+$), was prepared as for example 2,
20 steps (A) to (C). Step (B) was performed using 4-chloroaniline, and yielded (+/-)-(4-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzo[1,3]dioxole-5-carbonyl chloride in step (C).

Example 186

- 25 (+/-)-Benzo[1,3]dioxole-5-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amide

The title compound, MS (ISP): $m/e = 497.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with benzo[1,3]dioxole-5-carbonyl chloride in step (C).

Example 18

(+/-)-4-Cyano-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide

The title compound, MS (ISP): $m/e = 478.4$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with 4-cyano-benzoyl chloride in step (C).

Example 188

(+/-)-Benzo[b]thiophene-3-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amide

- 10 The title compound, MS (ISP): $m/e = 509.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with benzo[b]thiophene-3-carbonyl chloride in step (C).

Example 189

- 15 (+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-isonicotinamide

The title compound, MS (ISP): $m/e = 454.2$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using *p*-tolyl-amine, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-*p*-tolyl-amine, which was reacted with isonicotinoyl chloride in step (C).

20

Example 190

(+/-)-4-Cyano-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- 25 The title compound, MS (ISP): $m/e = 494.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-cyano-benzoyl chloride in step (C).

Example 191

(+/-)-N-(3-Methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-4-pyrazol-1-yl-benzamide

- 5 The title compound, MS (ISP): $m/e = 535.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 4-pyrazol-1-yl-benzoyl chloride in step (C).

Example 192

- 10 (+/-)-1-Methyl-1H-benzotriazole-5-carboxylic acid (3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 524.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 1-methyl-1H-benzotriazole-5-carbonyl chloride in step (C).

15

Example 193

(+/-)-5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

- 20 The title compound, MS (ISP): $m/e = 507.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 5-chloro-1-methyl-1H-pyrazole-4-carbonyl chloride in step (C).

Example 194

(+/-)-3,4-Dimethoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- 25 The title compound, MS (ISP): $m/e = 529.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dimethoxy-benzoyl chloride in step (C).

Example 195

(+/-)-2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid (3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

- The title compound, MS (ISP): $m/e = 501.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-methoxy-aniline, and yielded (+/-)-(3-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-ethyl-5-methyl-2H-pyrazole-3-carbonyl chloride in step (C).

Example 196

- (+/-)-2-Methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(4-trifluoromethoxy-phenyl)-benzamide

The title compound, MS (ISP): $m/e = 537.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-trifluoromethoxy-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine, which was reacted with 2-methyl-benzoyl chloride in step (C).

15

Example 197

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-(4-trifluoromethoxy-phenyl)-nicotinamide

- The title compound, MS (ISP): $m/e = 524.2$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-trifluoromethoxy-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine, which was reacted with nicotinoyl chloride in step (C).

Example 198

(+/-)-2-Ethyl-5-methyl-2H-pyrazole-3-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(4-trifluoromethoxy-phenyl)-amide

- The title compound, MS (ISP): $m/e = 555.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-trifluoromethoxy-aniline, and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine, which was reacted with 2-ethyl-5-methyl-2H-pyrazole-3-carbonyl chloride in step (C).

Example 199

(+/-)-Naphthalene-2-carboxylic acid (2-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 523.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 2-chloro-aniline, and yielded (+/-)-(2-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with naphthalene-2-carbonyl chloride in step (C).

Example 200

(+/-)-N-(2-Chloro-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 487.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 2-chloro-aniline, and yielded (+/-)-(2-chloro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 2-methyl-benzoyl chloride in step (C).

15

Example 201

(+/-)-Benzo[1,3]dioxole-5-carboxylic acid (3-dimethylamino-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 526.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-dimethylamino-aniline, and yielded (+/-)-(3-dimethylamino-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with benzo[1,3]dioxole-5-carbonyl chloride in step (C).

Example 202

(+/-)-N-(3-Dimethylamino-phenyl)-3,4-dimethoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

The title compound, MS (ISP): $m/e = 542.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-dimethylamino-aniline, and yielded (+/-)-(3-dimethylamino-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 3,4-dimethoxybenzoyl chloride in step (C).

Example 203

(+/-)-5-Chloro-N-(3-dimethylamino-phenyl)-2-fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzamide

- The title compound, MS (ISP): $m/e = 534.7$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-dimethylamino-aniline, and yielded (+/-)-(3-dimethylamino-phenyl)-[*cis*-(1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 5-chloro-2-fluoro-benzoyl chloride in step (C).

Example 204

- (+/-)-5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid (3-dimethylamino-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 520.3$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-dimethylamino-aniline, and yielded (+/-)-3-dimethylamino-phenyl-[*cis*-(1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with 5-chloro-1-methyl-1H-pyrazole-4-carbonyl chloride in step (C).

15

Example 205

(+/-)-N-(3-Acetylamino-phenyl)-2-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-trifluoromethyl-benzamide

- The title compound, MS (ISP): $m/e = 578.9$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 3-acetylamino-aniline, and yielded (+/-)-N-{3-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-ylamino]-phenyl}-acetamide, which was reacted with 2-methyl-3-trifluoromethyl-benzoyl chloride in step (C).

Example 206

(+/-)-Pyrazine-2-carboxylic acid (4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

- The title compound, MS (ISP): $m/e = 471.8$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 4-methoxy-aniline, and yielded (+/-)-(4-methoxy-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with pyrazine-2-carbonyl chloride in step (C).

Example 207

(+/-)-Naphthalene-2-carboxylic acid (2-acetylamino-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 546.8$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 2-acetylamino-aniline, and yielded (+/-)-N-{2-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-ylamino]-phenyl}-acetamide, which was reacted with naphthalene-2-carbonyl chloride in step (C).

Example 208

(+/-)-Isoxazole-5-carboxylic acid (2-fluoro-4-trifluoromethyl-phenyl)-[1-((1*S*,2*S*)-2-phenyl-cyclohexyl)-piperidin-4-yl]-amide

The title compound, MS (ISP): $m/e = 516.1$ ($M+H^+$), was prepared as for example 2, steps (A) to (C). Step (B) was performed using 2-fluoro-4-trifluoromethyl-aniline, and yielded (+/-)-(2-fluoro-4-trifluoro-phenyl)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine, which was reacted with isoxazole-5-carbonyl chloride in step (C).

Example 209

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-pyridin-2-yl-benzamide

(A) Reductive amination to (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine. A solution of (+/-)-*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-one (4.67 g, 18.14 mmol) and ammonium formate (10.60 g, 168.1 mmol) in technical methanol (48 ml) and water (5.1 ml) was treated with Pd/C (10 %, 2.11 g). The resulting suspension was stirred under an argon atmosphere for 18 h. The catalyst was filtered washing with methanol and the filtrate was evaporated, yielding crude (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (4.07 g, 87 %) as a colorless liquid, MS (ISP): $m/e = 259.3$ ($M+H^+$).

(B) Coupling of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine with 2-bromo-pyridine to yield (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-2-yl-amine. A suspension of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (1.00 g, 3.83 mmol) in toluene (30 ml) was degassed with a flow of argon for 10 minutes. Palladium(II) acetate (27.0 mg, 0.12 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 71.6 mg, 0.11 mmol), sodium *tert*-butoxide (0.45 g, 4.65 mmol) and 2-bromopyridine (0.49 g, 3.13 mmol) were added under argon. The flask was sealed and warmed to 70 °C for 3 hours. The mixture was diluted with ethyl acetate (30 ml) and

diethyl ether (30 ml) and washed three times with saturated sodium chloride solution. The organic phase was dried with sodium sulphate and evaporated, yielding an orange oil. Purification was achieved by flash chromatography (dichloromethane/methanol/25 % NH₃ 90:10:1). The title amine (0.326 g, 25 %) was obtained as a yellow oil, MS (ISP):
5 m/e = 336.3 (M+H⁺).

(C) Acylation to (+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-pyridin-2-yl-benzamide. To an aliquot of polystyrene-bound 2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine (PS-BEMP, 2.2 mmol/g, 0.120 g, 0.264 mmol) was added a solution of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
10 pyridin-2-yl-amine in THF (0.15 M, 0.6 ml, 0.088 mmol) and a solution of benzoyl chloride in THF (1.17 M, 0.3 ml, 0.35 mmol). The mixture was shaken at room temperature for 18 hours, then filtered washing with THF. The filtrate is injected into a preparative HPLC (Column: YMC Combiprep C18, CCASS05-052OWT, 50 x 20 mm I.D., S-5 µm 120 Å; Flux: 30 ml/min; Program: 0-0.5' 20 % acetonitrile in water + 0.05 %
15 HCO₂H; 9 5 % @ 2.5'; 95 % @ 4.75'; 20 % @ 4.80'; program end @ 5 min). The title compound, MS (ISP): m/e = 440.4 (M+H⁺), is obtained as a white solid (5.8 mg, 15 %).

Example 210

(+/-)-5-Methyl-isoxazole-3-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-2-yl-amide

20 The title compound, MS (ISP): m/e = 445.4 (M+H⁺), was prepared as for example 209, steps (A) to (C). Step (B) was performed using 2-bromo-pyridine and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-2-yl-amine, which was reacted with 5-methyl-isoxazole-3-carbonyl chloride in step (C).

Example 211

25 (+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-pyridin-3-yl-benzamide

The title compound, MS (ISP): m/e = 440.4 (M+H⁺), was prepared as for example 209, steps (A) to (C). Step (B) was performed using 3-bromo-pyridine as follows: A suspension of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (1.00 g, 3.88 mmol) in toluene (30 ml) was degassed with a flow of argon for 10 minutes. Tris-
30 (dibenzylideneacetone)dipalladium chloroform complex (124 mg, 0.12 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 76.0 mg, 0.12 mmol), sodium *tert*-butoxide (0.470 g, 4.89 mmol) and 3-bromopyridine (0.483 g, 3.06 mmol) were added

under argon. The flask was sealed and warmed to 70 °C for 3 hours. The mixture was diluted with ethyl acetate (30 ml) and diethyl ether (30 ml) and washed three times with saturated sodium chloride solution. The organic phase was dried with sodium sulphate and evaporated, yielding a red oil. Purification was achieved by flash chromatography (dichloromethane/methanol/25 % NH₃ 90:10:1). (+/-)-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-3-yl-amine (0.260 g, 20 %) was obtained as an orange foam, MS (ISP): *m/e* = 336.3 (M+H⁺). This was reacted with benzoyl chloride in step (C).

Example 212

(+/-)-5-Methyl-isoxazole-3-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-3-yl-amide

The title compound, MS (ISP): *m/e* = 445.4 (M+H⁺), was prepared as for example 209, steps (A) to (C). Step (B) was performed using 3-bromo-pyridine and yielded (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-3-yl-amine, which was reacted with 5-methyl-isoxazole-3-carbonyl chloride in step (C).

Example 213

(+/-)-N-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-N-pyridin-4-yl-benzamide

The title compound, MS (ISP): *m/e* = 440.4 (M+H⁺), was prepared as for example 209, steps (A) to (C). Step (B) was performed using 4-bromo-pyridine as follows: A suspension of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (0.303 g, 1.17 mmol) in toluene (10 ml) was degassed with a flow of argon for 10 minutes. Palladium(II) acetate (8.0 mg, 0.036 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 23.0 mg, 0.037 mmol), sodium *tert*-butoxide (0.280 g, 2.91 mmol) and 4-bromopyridine hydrochloride (0.194 g, 1.00 mmol) were added under argon. The flask was sealed and warmed to 70 °C for 3 hours. The mixture was diluted with ethyl acetate (10 ml) and diethyl ether (10 ml) and washed three times with saturated sodium chloride solution. The organic phase was dried with sodium sulphate and evaporated, yielding an orange oil. Purification was achieved by flash chromatography (dichloromethane/methanol/25 % NH₃ 65:10:1). (+/-)-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-pyridin-4-yl-amine (0.187 g, 47 %) was obtained as a light yellow foam, MS (ISP): *m/e* = 336.3 (M+H⁺). This was reacted with benzoyl chloride in step (C).


Example 214

(+/-)-5-Methyl-isoxazole-3-carboxylic acid [*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-pyrimidin-5-yl-amide

The title compound, MS (ISP): $m/e = 446.4$ ($M+H^+$), was prepared as for example 209, steps (A) to (C). Step (B) was performed using 5-bromo-pyrimidine as follows: A suspension of (+/-)-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-amine (1.46 g, 5.65 mmol) in toluene (35 ml) was degassed with a flow of argon for 10 minutes. Tris-(dibenzylideneacetone)dipalladium chloroform complex (179 mg, 0.17 mmol), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP, 108.0 mg, 0.17 mmol), sodium *tert*-butoxide (0.660 g, 6.87 mmol) and 5-bromopyrimidine (0.720 g, 4.53 mmol) were added under argon. The flask was sealed and warmed to 70 °C for 3 hours. The mixture was diluted with ethyl acetate (30 ml) and diethyl ether (30 ml) and washed three times with saturated sodium chloride solution. The organic phase was dried with sodium sulphate and evaporated, yielding a red oil. Purification was achieved by flash chromatography (dichloromethane/methanol/25 % NH₃ 90:10:1). (+/-)-[*cis*-1-(2-Phenyl-cyclohexyl)-piperidin-4-yl]-pyrimidin-5-yl-amine (0.392 g, 20.6 %) was obtained as an orange foam, MS (ISP): $m/e = 337.3$ ($M+H^+$). This was reacted with 5-methyl-isoxazole-3-carbonyl chloride in step (C).

Claims


1. Compounds of formula



wherein

- 5 R^1 is lower alkyl, $-(CH_2)_n$ -aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, $-OCF_3$, halogen, $-NR'R''$ or trifluoromethyl, or is heteroaryl;
- 10 R^2 is lower alkyl, $-(CH_2)_n$ -aryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, cyano, $-NR'R''$, hydroxy, or by a heteroaryl group, or is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl or halogen;
- R^3 is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl;
- R^4 is hydrogen or hydroxy;
- 15 A is $-S(O)_2-$ or $-C(O)-$;
- X,Y are independently from each other $-CH_2-$ or $-O-$, with the proviso that X and Y are not simultaneously $-O-$;
- $R'R''$ are independently from each other hydrogen, lower alkyl or $-C(O)$ -lower alkyl;
- n is 0, 1 or 2;
- 20 and pharmaceutically acceptable acid addition salts thereof.

2. Compounds of formula



5 in accordance with claim 1, wherein

R^1 is lower alkyl, benzyl or is phenyl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl;

10 R^2 is lower alkyl, benzyl, thiophenyl or is phenyl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl, nitro, amino, hydroxy or $-NHC(O)$ -lower alkyl;

R^3 is pyridin-3-yl, pyridin-4-yl or is phenyl, unsubstituted or substituted by halogen or lower alkyl;

R^4 is hydrogen or hydroxy;

15 A is $-S(O)_2-$ or $-C(O)-$;

X,Y are independently from each other $-CH_2-$ or $-O-$, with the proviso that X and Y are not simultaneously $-O-$;

and pharmaceutically acceptable acid addition salts thereof.

20 3. Compounds according to claim 1 or 2, wherein X and Y are both $-CH_2-$, A is $-S(O)_2-$, R^3 is unsubstituted phenyl and R^4 is hydrogen.

4. Compounds according to claim 3, which are

(+/-)-3,4-dichloro-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide,
 (+/-)-4-methoxy-N-(3-methoxy-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-benzenesulfonamide,
 25 (+/-)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-

benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-4-methyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 5 benzenesulfonamide,
 (+/-)-4-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-trifluoromethyl-
 phenyl)-benzenesulfonamide or
 (+)-4-methoxy-N-phenyl-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzenesulfonamide.

10 5. Compounds according to claim 1 or 2, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydrogen.

6. Compounds according to claim 5, which compounds are
 (+/-)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide,
 (+/-)-4-fluoro-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-benzamide,
 15 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-3-
 trifluoromethyl-benzamide or
 (+/-)-N-(4-chloro-phenyl)-3-methoxy-N-[*cis*-1-(2-phenyl-cyclohexyl)-piperidin-4-yl]-
 benzamide.

20 7. Compounds according to claim 1 or 2, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydroxy.

8. Compounds according to claim 7, which are
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-
 methoxy-benzamide,
 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-
 25 methoxy-benzamide,
 (+/-)-4-fluoro-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-*p*-tolyl-
 benzamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-N-(3-methoxy-
 phenyl)-benzamide or
 30 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-3-methoxy-N-*p*-tolyl-
 benzamide.

9. Compounds according to claim 1 or 2, wherein X and Y are both $-\text{CH}_2-$, A is $-\text{S}(\text{O})_2-$, R^3 is unsubstituted phenyl or phenyl, substituted by chloro, fluoro or methyl, and R^4 is hydroxy.

10. Compounds according to claim 9, which are

- (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide,
 (+)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-
 5 benzenesulfonamide,
 (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide,
 (+/-)-N-{*cis*-1-[2-(4-chloro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-N-phenyl-benzenesulfonamide,
 10 (+/-)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-N-phenyl-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-*o*-tolyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-
 15 methoxy-benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-methoxy-phenyl)-benzenesulfonamide,
 20 (+/-)-N-{*cis*-1-[2-(4-fluoro-phenyl)-2-hydroxy-cyclohexyl]-piperidin-4-yl}-4-methoxy-N-(3-methoxy-phenyl)-benzenesulfonamide or
 (+/-)-N-[*trans*-1-(2-hydroxy-2-phenyl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide.

11. Compounds according to claim 1 or 2, wherein X and Y are both -CH₂-, A is
 25 -S(O)₂-, R³ is pyridin-3-yl or pyridin-4-yl and R⁴ is hydroxy.

12. Compounds according to claim 11, which are

- (+/-)-N-(4-chloro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-
 30 phenyl-benzenesulfonamide,
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-phenyl-benzenesulfonamide,
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide,
 35 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-4-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-

trifluoromethyl-phenyl)-benzenesulfonamide or
 (+/-)-N-[*cis*-1-(2-hydroxy-2-pyridin-3-yl-cyclohexyl)-piperidin-4-yl]-4-methoxy-N-(3-trifluoromethyl-phenyl)-benzenesulfonamide.

13. Compounds according to claim 1 or 2, wherein X is $-\text{CH}_2-$, Y is $-\text{O}-$, A is
 5 $-\text{S}(\text{O})_2-$, R^3 is unsubstituted phenyl and R^4 is hydroxy.

14. A compound according to claim 13, which is
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-4-methoxy-benzenesulfonamide.

15. Compounds according to claim 1 or 2, wherein X is $-\text{CH}_2-$, Y is $-\text{O}-$, A is
 10 $-\text{C}(\text{O})-$, R^3 is unsubstituted phenyl and R^4 is hydroxy.


16. A compound according to claim 15, which is
 (+/-)-N-(4-fluoro-phenyl)-N-[*cis*-1-(4-hydroxy-4-phenyl-tetrahydro-pyran-3-yl)-piperidin-4-yl]-3-methoxy-benzamide.

17. Compounds according to claim 1, wherein X and Y are both $-\text{CH}_2-$, A is
 15 $-\text{C}(\text{O})-$ and R^3 is heteroaryl, unsubstituted or substituted by halogen or lower alkyl.

18. Compounds according to claim 1, wherein X and Y are both $-\text{CH}_2-$, A is
 $-\text{C}(\text{O})-$, R^2 is heteroaryl, unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl or halogen and R^4 is hydrogen.

19. Processes for preparation of compounds of formula I in accordance with claim
 20 1, which process comprises

a) reacting a compound of formula




with a compound of formula



25 in the presence of a base and/or a proton scavenger


to a compound of formula

- 84 -



wherein X, Y, R¹, R² and R³ are as defined above, or

b) reacting a compound of formula




5 with a compound of formula




in the presence of a base and/or a proton scavenger

to a compound of formula



10 wherein X, Y, R¹, R² and R³ are as defined above, or


c) reacting a compound of formula



with a compound of formula




to a compound of formula




wherein A, X, Y, R¹, R² and R³ are as defined above, or

d) reacting a compound of formula




5

with a compound of formula



to a compound of formula



10 wherein A, X, Y, R¹, R² and R³ are as defined above, and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

20. A compound according to any one of claims 1 – 18, whenever prepared by a process as claimed in claim 19 or by an equivalent method.

15 21. A medicament containing one or more compounds as claimed in any one of claims 1 – 18 and pharmaceutically acceptable excipients.

22. A medicament according to claim 21 for the treatment of illnesses based on the glycine uptake inhibitor.

23. A medicament according to claims 21 and 22, wherein the illnesses are psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other
5 diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

24. The use of a compound as claimed in any one of claims 1 – 18 for the manufacture of medicaments for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in
10 which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

25. The invention as herein before described.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/001211

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 A61K31/4468 C07D409/12 C07D401/08 C07D405/04
C07D413/12 C07D413/14 A61P25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/81308 A (MADDAFORD SHAWN P ; SLASSI ABDELMALIK (CA); TSE HOI LUN ALLAN (CA); FR) 1 November 2001 (2001-11-01) the whole document	1-25
A	WO 99/45011 A (JANSSENS FRANS EDUARD ; JANSSEN PHARMACEUTICA NV (BE); KENNIS LUDO EDM) 10 September 1999 (1999-09-10) the whole document	1-25
P, A	WO 03/013527 A (SCHERING CORP) 20 February 2003 (2003-02-20) the whole document	1-25

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

25 June 2004

Date of mailing of the international search report

02/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/001211

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0181308	A	01-11-2001	AU 5454601 A	07-11-2001
			WO 0181308 A2	01-11-2001
			CA 2406652 A1	01-11-2001
			EP 1296950 A2	02-04-2003
			US 2003176461 A1	18-09-2003
<hr/>				
WO 9945011	A	10-09-1999	AU 3254499 A	20-09-1999
			BG 104686 A	30-04-2001
			BR 9907953 A	24-10-2000
			CA 2322136 A1	10-09-1999
			CN 1291984 T	18-04-2001
			EE 200000483 A	15-02-2002
			WO 9945011 A1	10-09-1999
			EP 1058684 A1	13-12-2000
			HR 20000524 A1	28-02-2001
			HU 0101281 A2	28-09-2001
			JP 2002505332 T	19-02-2002
			NO 20004432 A	02-11-2000
			PL 342818 A1	02-07-2001
			SK 13092000 A3	12-03-2001
			TR 200002570 T2	21-12-2000
<hr/>				
WO 03013527	A	20-02-2003	CA 2455861 A1	20-02-2003
			EP 1411944 A1	28-04-2004
			WO 03013527 A1	20-02-2003
			US 2003216380 A1	20-11-2003
<hr/>				